Table 3 Cohort characteristics
Characteristic | Site 1 | Site 2 | Site 3 | Site 4 | Site 5 | Site 6 | All sites |
|---|---|---|---|---|---|---|---|
Total sample size | 149 | 149 | 147 | 149 | 102 | 150 | 846 |
Follow up time, months | 12 | 36 | 12 | 12 | 12 | 36 | --- |
Median age at ART initiation, years [IQR] | 35 [30–40] | 35 [30–43] | 34 [29–40] | 33 [29–42] | 35 [31–41] | 37 [31–46] | 35 [30–42] |
Sex, % female | 63 | 52 | 68 | 66 | 45 | 58 | 60 |
Median CD4 at ART initiation, cells/μL [IQR]a | 149 [97–211] | 127 [67–206] | 136 [84–199] | 150 [77–237] | 140 [74–273] | 160 [106–209] | 145 [86–212] |
Regimen at ART initiation, % of patients | |||||||
TDF-containing regimen | 36 | 86 | 80 | 15 | 54 | 80 | 59 |
AZT-containing regimen | 30 | 5 | 13 | 4 | 30 | 7 | 14 |
ABC-containing regimen | 0 | 5 | 0 | 76 | 0 | 0 | 14 |
d4T-containing regimen | 34 | 5 | 7 | 5 | 16 | 13 | 13 |